
CNTB Stock Forecast & Price Target
CNTB Analyst Ratings
Bulls say
Connect Biopharma Hldgs is poised for success with its promising next-generation antibody, rademikibart, which has shown positive results in clinical trials for asthma and COPD and has received an Outperform rating and $8 price target. The drug's unique mechanism and potential in the Chinese market provide a strong foundation for financial growth, with potential peak revenue of $2 billion upon FDA approval. With upcoming Phase 2 studies and an expanding pipeline, the company is on track for significant success.
Bears say
Connect Biopharma Hldgs is playing the high-risk, high-reward game with its clinical studies of rademikibart, and their portfolio diversification is currently heavily reliant on its success. However, the differentiation of rademikibart may not be convincing enough, considering that its early signs of efficacy are from uncontrolled and cross-study evidence and the general skepticism around using biologics for acute care. With its sole lead candidate being tested in acute settings, any negative results from the ongoing clinical trials pose a significant risk to the company and its stock value.
This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.
CNTB Analyst Forecast & Price Prediction
Start investing in CNTB
Order type
Buy in
Order amount
Est. shares
0 shares